Overview

ALS Reversals - Lunasin Regimen

Status:
Completed
Trial end date:
2017-09-13
Target enrollment:
Participant gender:
Summary
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group. Participants will receive a Lunasin regimen and will be asked to register for an account of PatientsLikeMe website, where after the initial in-clinic visit, they will be asked to enter specific data.
Phase:
Phase 2
Details
Lead Sponsor:
Richard Bedlack, M.D., Ph.D.